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1. INTRODUCTION 
ACE Inhibitors are the first class of drugs that represents antihypertensive 
agents which were designed and developed with the basis of a well–defined 
pathophysiological axis of arterial hypertension, a vascular disorder which is now 
becoming one of the major causes of morbidity and mortality, not only in developed 
societies but also in the highly populated developing countries.1 
Since their initial development in the 1970s as a therapy for hypertension, 
ACE inhibitors have become established as cornerstones in the treatment of 
hypertension, heart failure and myocardial infarction (MI).2 
They are also considered as the first-line choice of treatment of hypertension 
in younger patients, and a second-line choice in all patient groups.3 
 
1.1 MECHANISM OF ACTION 
These agents inhibit angiotensin-converting enzyme (ACE), thus preventing 
conversion of angiotensin I to angiotensin II, which is a potent vasoconstrictor and 
stimulator of aldosterone secretion (aldosterone suppression reduces sodium and 
water retention). ACE inhibitors also prevent the breakdown of bradykinin (a potent 
vasodilator). The net result is vasodilatation, decreased peripheral vascular 
resistance, decreased blood pressure, increased cardiac output, and a relative 
increase in renal, cerebral and coronary bloodflow.4 
flow.4.  
1.2 INDICATIONS 
The main indications of ACE inhibitors are as follows 
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1.2.1 Hypertension 
An ACE inhibitor may be the most common appropriate initial drug for hypertension 
in younger patients; some patients aged over 55 years, and those with primary 
aldosteronism respond less well. ACE inhibitors are particularly indicated for 
hypertension in patients with type 1 diabetes with nephropathy. They may reduce 
blood pressure very rapidly in some patients particularly in those receiving diuretic 
therapy; the first dose should preferably be given at bed time. 
1.2.2 Heart failure 
ACE Inhibitors are used in all grades of heart failure, usually combined with a beta 
blocker .potassium supplements and potassium sparing diuretics. 
However, a low dose of spironolactone may be beneficial in severe heart failure and 
can be used along with an ACE inhibitor provided serum potassium is monitored 
carefully Profound first-dose hypotension may occur when ACE inhibitors are 
introduced to patients with heart failure who are already taking a high dose of loop 
diuretic (e.g. furosemide 80mg daily or more).Temporary withdrawal of loop diuretics 
reduces the risk, but may cause severe rebound pulmonary oedema. 
Therefore for patients on high doses of loop diuretics, the ACE inhibitor may need to 
initiated under specialist supervision, An ACE inhibitor can be initiated in patients 
who are receiving a low dose of a diuretic or who are not otherwise at risk of serious 
hypotension; nevertheless, care is required and a very low dose of the ACE inhibitor 
is given initially. 
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1.2.3 Diabetic Nephropathy 
ACE inhibitors are particularly useful for people with diabetic nephropathy 
because they significantly decrease the amount of protein in the urine and can also 
prevent or slow the progression of diabetes-related kidney disease. The kidney 
benefits of ACE inhibitors are so robust that the  healthcare providers sometimes 
prescribe them for people with diabetic nephropathy who have normal blood 
pressure. 
1.2.4Prophylaxis of Cardiovascular Events 
ACE inhibitors are used in the early and long-term management of patients who had 
a myocardial infarction; ACE inhibitors may also have a role in preventing 
cardiovascular events. 
ACE inhibitors should be initiated under specialist supervision and with careful 
clinical monitoring in those with severe heart failure or in those: 
 with hypovolaemia; 
 with hyponatremia (plasma-sodium concentration below 130mmol/litre); 
 with hypotension (systolic blood pressure below 90mmHg); 
 with unstable heart failure; 
 receiving high dose vasodilator therapy; 
 known renovascular disease.5 
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1.3CLASSIFICATION 
ACE Inhibitors can be divided into three groups based on their molecular structure:  
 Sulfhydryl-containing agents:  
o Captopril , the first ACE inhibitor  
 Dicarboxylate-containing agents:  
o Enalapril  
o Ramipril  
o Quinapril  
o Perindopril  
o Lisinopril  
o Benazepril  
 Phosphonate-containing agents:  
o Fosinopril 
Based on the effectiveness and drug choice depending on the indications, ACE 
Inhibitors can be classified as:  
 For high blood pressure: Benazepril, Enalapril, and Lisinopril  
 For heart failure: Captopril, and Enalapril  
 After a heart attack: Lisinopril  
 For diabetics: Ramipril  
 For people with kidney disease: Benazepril, and Ramipril.6 
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1.4PHARMACOKINETICS 
1.4.1 Captopril 
Onset 30 minutes, duration 8 to 12 hours, and 70% absorbed. Peak concentrations 
about 1 hour; 25% protein bound, volume of distribution 0.7 L/kg, 50% hepatic 
metabolism, renal elimination, and half-life 1.9 hours.  
1.4.2 Enalapril 
Onset 1 to 4 hours, duration 12 to 24 hours, and 60% absorbed. Peak 
concentrations 1 hour, 50% protein bound, active hepatic metabolite (enalaprilat) 
which is renally eliminated. Half-life: enalapril 1.3 hours; enalaprilat 11 hours. 
1.4.3 Lisinopril 
Onset 1 hour, duration 24 hours, and about 25% absorbed. Peak concentration 6 to 
8 hours, minimal protein binding, volume of distribution 124 litres, elimination: mostly 
faecal followed by renal and half-life 12 hours.  
1.4.4 Perindopril 
Onset 1.5 hours, duration 24 hours, 20% to 30% absorbed, and 60% protein bound. 
Volume of distribution 0.33 L/kg, extensive hepatic metabolism, 75% renal and 25% 
faecal elimination of metabolites. Half-life 1 hour.7 
 
1.5CONTRAINDICATIONS 
ACE inhibitors are contraindicated in patients with hypersensitivity to ACE inhibitors. 
(Including angioedema) 
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1.5.1 Hepatic Impairment 
Use of prodrugs such as cilazapril, enalapril, fosinopril, imidapril, moexipril, 
Perindopril, quinapril, ramipril and trandolapril requires close monitoring in patients 
with impaired liver function. 
1.5.2 Renal Impairment 
ACE inhibitors should be used with caution and the response monitored, 
hyperkalemia and other side effects are more common; the dose may be needed to 
be reduced. 
1.5.3 Pregnancy 
ACE inhibitors should be avoided in pregnancy unless essential. They may 
adversely affect foetal and neonatal blood pressure control and renal function; skull 
defects and olihohydramnios have also been reported. 
1.5.4 Breast Feeding 
Information on the use of ACE inhibitors in breast feeding is limited. 
Cilazapril,Fosinopril, Imidapril, Moexipril, Perindopril, Ramipril and Tranolapril are not 
recommended; alternative treatment options, with better established safety 
information during breast-feeding are available. Captopril, Enalapril and Quinapril 
should be avoided in the first few weeks after delivery, particularly in preterm infants, 
due to the risk profound neonatal hypotension; ifessential, they may be used in 
mothers breastfeeding older infants -the infant’s blood pressure should be 
monitored.8 
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1.6DRUG INTERACTION 
1.6.1 Albumin 
Profound hypotension developed in a patient on captopril after receiving 4% albumin. 
The albumin contained 10 IU/mL of prekallikrein activating factor (PKA) PKA 
activates bradykinin while ACE inhibitors block the biodegradation of bradykinin, 
potentially causing persistent hypotension in this setting.  
1.6.2 Allopurinol 
Concomitant use of captopril and allopurinol has rarely been associated with a 
serum sickness or Stevens-Johnson syndrome  
1.6.3 Antihyperglycemic Agents 
Hypoglycaemia has been reported with simultaneous use of ACE inhibitors and 
insulin or oral hypoglycemic agents. 
1.6.4 Cyclosporine 
The combination of cyclosporine and ACE inhibitors may rarely cause acute renal 
failure. 
1.6.5 Diuretics 
The combination of ACE inhibitors and potassium-sparing diuretics may cause 
hyperkalemia. 
1.6.6 Hemodialyzer Membranes 
Several cases of life-threatening anaphylactic reactions have been reported in 
patients receiving ACE inhibitors and hemodialysis with a polyacrylonitrile membrane 
dialyzer (AN69).  
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1.6.7 Nonsteroidal Anti-inflammatory Drugs 
The combination of NSAIDs and ACE inhibitors may cause renal insufficiency  
1.6.8 Wasp Venom 
Anaphylactic reactions have been reported after co-administration of enalapril and 
wasp venom, presumably due to amplification of the inflammatory response induced 
by the kallikrein-kinin system.8 
1.7 ADVERSE EFFECTS 
 ACE Inhibitors can cause profound hypotension and renal impairment and 
a persistent dry cough 
 They can also cause angioedema (onset may be delayed; higher 
incidence reported in Afro-Caribbean patients), rash (which may be 
associated with pruritisand urticaria), pancreatitis 
 Upper respiratory-tract symptoms such as sinusitis, rhinitis and sore throat 
 Gastrointestinal effects reported nausea, vomiting, dyspepsia,diarrhoea, 
constipation and abdominal pain 
 Altered liver function tests, cholestatic jaundice,hepatitis, fulminant hepatic 
necrosis  and hepatic failure have been reported- discontinue if marked 
elevation of hepatic enzymes or jaundice 
 Hyperuricaemia 
 Hyperkalemia 
 Hypoglycaemia 
 Blood disorders such as thrombocytopenia, leucopenia, neutropenia and 
haemolytic anaemia have also been reported. 
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Other reported adverse effects include  
 Headache 
 Dizziness 
 Fatigue 
 Malaise 
 Taste disturbance 
 Paraesthesia 
 Bronchospasm 
 Fever 
 Serositis 
 Vasculitis 
 Myalgia 
 Arthralgia 
 Raised erythrocyte sedimentation rate (ESR)  
 Eosinophilia 
 Leucocytosis 
 Photosensitivity. 
1.8TOXICOLOGY 
The toxic effect of an ACE inhibitor is an extension of its pharmacologic effect. The 
elevation in bradykinin concentration appears to be the primary cause of both ACE 
inhibitor-induced angioedema and cough. ACE inhibitors may also inhibit the 
metabolism of enkephalins and potentiate their opioid effect, which includes lowering 
blood pressure.                              
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1.9COMBINATION PRODUCTS 
Products incorporating an ACE inhibitor with a thiazide diuretic or a calcium-channel 
blocker are available for the management of hypertension. Use of these combination 
products should be reserved for patients whose blood pressure has not responded 
adequately to a single antihypertensive drug and who have been stabilised on the 
individual components in the same proportions.8, 9 
 
1.10CAPTOPRIL 
Dose 
 Initial dosage: 25 mg orally 2 or 3 times daily; may increase to 50 mg orally 2 
or 3 times daily after 1 to 2 weeks; Maintenance dosage: 25 to 150 mg orally 
2 or 3 times daily 
 Maximum dosage: 450 mg/day 
Contraindications: 
 Angioedema history related to prior therapy with an ACE inhibitor. 
 Hypersensitivity to captopril or to any other ACE inhibitor. 
 Coadministration with aliskiren in patients with diabetes 
 Concomitant neprilysin inhibitors (eg,sacubitril) or within 36 hours of switching 
to or fromsacubitril/valsartan10 
Adverse Effects 
Angina pectoris  
 Incidence: 0.2% to 0.3%            
 Angina pectoris has been reported as occurring in 0.2% to 0.3% of patients  
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receiving captopril in clinical trials. Increased lactate production which may indicate 
myocardial ischemia and may exacerbate angina has been reported, with episodes 
of angina leading to drug withdrawal. In contrast, captopril may enhance regional 
coronary blood flow and has been used to treat angina pectoris. 
Chest pain 
Chest pain has been observed in approximately 1 in 100 patients receiving captopril 
in clinical trials. 
Flushing 
 Incidence:0.2% to 0.5% 
 Flushing or pallor has been reported as occurring in 2 to 5 of 1000 
Patients receiving captopril  
Hypotension 
Although excessive hypotension was rare in patients treated with captopril for 
hypertension, it is a possibility in volume or salt depleted patients, patients with heart 
failure, or patients undergoing renal dialysis. 
Gastrointestinal Effects 
 
Diarrhoea 
 Incidence: 0.5% to 2%  
Hepatic Effects 
Hepatotoxicity 
Immunologic Effects 
 Anaphylactoid reaction 
 Renal effects  
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 Acute renal failure 
 Hyperuricaemia 
 Glomerulonephritis 
 Nephrotic syndrome 
 Nephrotoxicity 
 Proteinuria 
Reproductive Effects 
 Erectile dysfunction 
Respiratory Effects 
 Bronchospasm 
 Cough 
Other 
 Angioedema. 11 
 
1.11ENALAPRIL  
Dose 
 Initial dosage: 5 mg orally once daily 
 Maximum dosage: 40 mg orally daily; may divide dose and administer twice 
daily. 
 Usual dosage range: 10 to 40 mg/day in single or divided   doses. 
 Concomitant medication: Initiate at 2.5 mg/day if co- administered with a low-
dose diuretic.12 
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Indications 
Enalapril maleate oral tablets and oral solutions are indicated for the treatment of 
hypertension in adults and children older than 1 month. 
Contraindications 
 Concomitant aliskiren use in patients with diabetes. 
 Concomitant neprilysin inhibitors (e.g. sacubitril) or within 36 hours of 
switching to or from sacubitril/valsartan  
 Hereditary or idiopathic angioedema  
 History of angioedema related to prior therapy with an ACE Inhibitor  
 Hypersensitivity to enalapril  or an ACE inhibitor  
Adverse effects 
Common or very common 
 Bronchitis 
 Syncope 
 Hyperuricaemia 
Uncommon 
 Angina 
 Anxiety 
 Arrhythmias 
 Chest pain 
 Decreased libido 
 Flushing 
 Impotence.13 
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1.12RAMIPRIL 
Dose 
The recommended initial dose of ramipril for the treatment of hypertension is 2.5 mg 
orally once daily in patients not receiving a diuretic, adjusted according to response. 
The usual maintenance dose is 2.5 to 20 mg daily, which may be administered as a 
single dose or in 2 divided doses. If diuretic therapy is used concurrently, a decrease 
in the starting dose of ramipril may be required.14 
Contraindications 
 Concomitant use with a neprilysin inhibitor or use within 36 hours of switching 
to or from sacubitril/valsartan, a neprilysin inhibitor,  
 Concomitant aliskiren use in patients with diabetes  
 History of angioedema related to prior therapy with an ACE inhibitor, 
 Hypersensitivity to ramipril, any component of this product, or to anotherACE 
inhibitor. 
Adverse Effects 
Common or very common 
 Bronchitis 
 Dyspnoea. 
 Muscle Cramps 
 Stomatitis 
 Syncope 
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Uncommon 
 Angina 
 Anxiety 
 Arrhythmias 
 Chest Pain 
 Decreased Libido 
 Depression 
 Impotence 
 Loss of Appetite 
 Myocardial Infarction 
 Nervousness 
 Palpitations 
 Peripheral Oedema 
 Sweating 
 Tachycardia 
 Visual Disturbances 
Rare 
 Confusion 
 Impaired hearing 
 Onycholysis 
 Tinnitus 
 Tremor 
 Hyperuricaemia 
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Frequency Not Known 
 Alopecia 
 Cerebrovascular Accident 
 Erythema Multiforme 
 Pemphigoid Exanthema 
 Precipitation Or Exacerbation of Raynaud’s Syndrome 
 Skin Reactions 
 Sleep Disturbance 
 Stevens-Johnson Syndrome 
 Toxic Epidermal Necrolysis.15 
 
1.13QUINAPRIL 
Dose 
Adult 
 Initially 10 mg once daily; 
 Maintenance 20–40 mg daily in up to 2 divided doses; 
 Maximum 80 mg per day. 
Elderly 
 Initially 2.5 mg once daily; 
 Maintenance 20–40 mg daily in up to 2 divided doses;  
  Maximum 80 mg per day. 
Contraindications 
 History of angioedema related to prior therapy with an ACE inhibitor  
 Concomitant aliskiren use in patients with diabetes.  
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 Concomitant use with a neprilysin inhibitor or use within 36 hours of switching to 
or from sacubitril/valsartan, a neprilysin inhibitor. 
 Hypersensitivity to quinapril or any other component of the product.  
Adverse Effects 
 Impotence 
 Asthenia 
 Back Pain 
 Chest Pain 
 Depression 
 Flatulence 
 Insomnia16 
1.14FOSINOPRIL SODIUM 
Dose 
 Initial dose, 10 mg once daily 
 Usual dose, 20 and 40 mg daily 
 Maximum dose, 80 mg daily  
The dose should be adjusted according to the patients response at peak and trough 
plasma levels, 2 to 6 hours and 24 hours respectively, with divided daily doses 
indicated if blood pressure control is inadequate with once daily dosing. 17 
Contraindications 
Hypersensitivity to fosinopril or other ACE inhibitors  
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Adverse effects 
 Blurred Vision 
 Chest Pain or Discomfort 
 Chills 
 Cold Sweats 
 Confusion 
 Dizziness, Faintness, or Light Headedness  
 Fast, Slow or Irregular Heartbeat 
 Pounding or Rapid Pulse 
 Sweating 
 Unusual Tiredness or Weakness.18 
 
1.15PERINDOPRIL 
Dose 
For the treatment of essential hypertension, the recommended initial dosage 
of Perindopril erbumine is 4 mg orally once daily. The Perindopril dosage may be 
titrated up to a maximum of 16 mg daily; however, the usual maintenance dosage is 
4 to 8 mg daily given as a single daily dose. The daily Perindopril dose may be also 
be given in 2 divided doses 
Concomitant Use with Diuretic Therapy 
In patients already taking diuretic therapy, symptomatic hypotension may 
occur with the first dose of Perindopril. To minimize this risk, consider reducing the 
diuretic dose prior to initiating Perindopril.19 
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Contraindications 
 Concomitant aliskiren use in diabetic patients  
 Hereditary or idiopathic angioedema  
 Hypersensitivity (including angioedema) to Perindopril, any component of the 
Product or other ACE inhibitors.  
Adverse Effects 
 Asthenia.  
 Mood Disturbances.  
 Sleep Disturbances. 20 
1.16LISINOPRIL 
Dose 
 Initial dose,10 mg once daily 
 Maintenance dose, 20 mg once daily 
 Maximum dose, 80 mg per day  
Contraindications 
 Concomitant aliskiren use in diabetic patients  
 Concomitant neprilysin inhibitors (e.g., sacubitril) or within 36 hours of 
Switching to or from sacubitril/valsartan  
 Hereditary or idiopathic angioedema  
 History of angioedema or hypersensitivity with prior ACE inhibitoruse  
 Hypersensitivity to Lisinopril or product components 
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Adverse effects  
Common 
 Vertigo 
 Asthenia 
 Hepatotoxicity 
 Cerebrovascular Accident 
 Confusion 
 Impotence 
 Mood Changes 
 Myocardial Infarction 
 Palpitation 
 Sleep Disturbances 
 Tachycardia 
Rare 
 Alopecia 
 Dry Mouth 
 Gynaecomastia. 
Very Rare 
 Allergic Alveolitis 
 Pemphigus 
 Profuse Sweating 
 Pulmonary Infiltrates. 21 
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1.18 BENAZEPRIL 
Dose 
Initial, in patients not receiving a diuretic, 10 mg orally once daily; maintenance, 20 to 
40 mg orally once daily or in 2 equally divided doses. Divided doses may be more 
effective for trough or pre-dosing blood pressure than once daily regimens. Doses up 
to 80 mg/day may increase response but experience is limited. In patients receiving 
a diuretic, 5 mg orally once daily.22 
Contraindications 
 Angioedema history  
 Concomitant aliskiren use in diabetic patients  
 Concomitant neprilysin inhibitors (e.g. sacubitril) or within 36 hours of  
switching to or from sacubitril/valsartan 
 Hypersensitivity to benazepril, other ACE inhibitors, or to any component of 
the product. 
Adverse effects 
 Blurred vision 
 Chest pain or discomfort 
 Chills 
 Cold sweats 
 Confusion 
 Dizziness, faintness or light headedness when getting up from a lying or 
sitting position suddenly 
 Fast, slow or irregular heartbeat 
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 Pounding or rapid pulse 
 Sweating 
 Unusual tiredness or weakness.23 
In view of the increasing number of available antihypertensive agents, clinicians are 
faced with the need to become familiar with the potential drug related outcomes. 
Unfortunately, adverse antihypertensive drug reactions cannot always be predicted 
from the pharmacological profile and only prolonged clinical experience will reveal 
their adverse effects. 
In this study we observed the incidence of cardiac events and prevalence of 
Hyperuricaemia, Liver diseases in Hypertensive patients with ACE inhibitors in a 
rural population. 
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2. REVIEW OF LITERATURE 
In the year 2017, Aslam Mand his colleagues performed a comparative study on 
Efficacy and Tolerability of Antihypertensive Drugs in Diabetic and Non diabetic 
Patients. The study was conducted on 200 hypertensive patients with diabetes and 
230 hypertensive patients without (Three hospitals) diabetes. The study was 
conducted for 4 months. After 4 months; patients were assessed for efficacy by 
monitoring blood pressure (BP) and tolerability by assessing safety profile on renal 
function, liver function as well as lipid profile. Adverse effects observed were dry 
cough, pedal edema, dizziness, muscular cramps, constipation, palpitations, 
sweating, vertigo, tinnitus, paresthesia, and sexual dysfunction. All classes of 
antihypertensives were found to control blood pressure significantly in both groups of 
patients that is diabetic patients with hypertension and non-diabetic patients 
with hypertension.24 
In the year 2017, Forner D et al performed a case study on Ramipril-associated 
cholestasis in the setting of recurrent drug-induced liver injury .Rare reports of ACEI-
induced hepatotoxicity have been described, most notably a cholestatic pattern of 
injury related to captopril. A 67-year-old male presented to the emergency 
department with a three-week history of jaundice, pruritis and weakness. Eight 
weeks before, he began taking ramipril and clopidogrel. His past medical history was 
significant for previous acute cholestatic liver injury approximately 20 years earlier, 
which was attributed to methimazole. AST, ALT, Serum Bilirubin was abnormal 
abdominal ultrasound and magnetic resonance cholangiopancreatography showed 
no bile duct obstruction. This case representsthe first described cross reactivity  
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between ramipril and methimazole, illustrating the complex and poorly understood 
nature of DILI. Despite the relatively few instances of ACEI – induced liver 
hepatotoxicity, consideration should be given to discontinuation of ramipril in 
situations of unknown liver damage.25 
In the year 2017, Hallberg Pet al conducted a comparative study on Clinical 
Factors associated between Patients With Angiotensin-Converting Enzyme Inhibitor-
Induced Angioedema and Cough. Data on patients with angioedema or cough 
inducedby ACE inhibitors were collected from the Swedish database of 
spontaneously reported ADRs or from collaborating clinicians. Wilcoxon rank sum 
test, Fisher's exact test, and odds ratios (ORs) with 95% CIs were used to test for 
between-group differences. Angioedema cases were seen more often in male 
patients and had longer time to onset and higher doses than those with cough. A 
multiple model containing the variables smoking, concurrent calcium channels 
blocker. Smoking, co medication with selective calcium channel blockers, male sex, 
and longer treatment time were associated with ACE inhibitor-induced angioedema 
rather treatment, male sex, and time to onset accounted for 26% of the variance 
between the groups than cough.
26 
In the year 2016, Francesca Viazzi et al conducted a study on Increased 
Serum Uric Acid Levels blunt the Antihypertensive Efficacy of Lifestyle Modifications 
in Children at Cardiovascular Risk Preliminary studies in children highlighted uric 
acid as a potentially modifiable risk factor for the prevention and treatment of 
hypertension. The risk of hypertension at follow-up was associated with body mass 
index and systolic blood pressure z-score at baseline and inversely related to delta  
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body mass index, whereas the risk of showing hypertension ≥99th percentile was  
more than doubled for each baseline 1 mg/dL increase of serum uric acid .Uric acid 
is a powerful determinant of blood pressure over time, independent of lifestyle 
modifications.27 
In the year 2016, Loprinzi PDand Loenneke JP  performed a retrospective 
study on the effects of antihypertensive medications on physical function. The 
purpose of this study was to examine whether several antihypertensive medication 
classes were associated with several measures of physical function in a national 
sample of middle-to-older age adults. Data from the 2004 -2009 and 2011-2016 
NHANES were used. Antihypertensive medication use was assessed from an 
interviewer, andincluded angiotensin converting enzyme (ACE) inhibitors, 
peripherally-acting anti adrenergic agents and centrally-acting anti adrenergic 
agents. Physical function-related parameters included objectively-measured lower 
extremity isokinetic knee extensor strength (IKES), objectively-measured grip 
strength, laboratory-assessed walking performance (8 and 20 ft walk tests) and self-
reported physical activity engagement. Antihypertensive medication use, particularly 
ACE inhibitors, is associated with various measures of reduced physical function. 
Clinicians are encouraged to monitor the long-term mobility function of their patients 
on antihypertensive medications.28 
In the year 2016,Imprialos KP  et alperformed a prospective study on 
Current challenges in antihypertensive treatment in the elderly. In the elderly 
population, elevated BP has been related with increased cardiovascular risk. Trials 
on this population have shown great benefits for morbidity and mortality from 
reducing Systolic BP (SBP) levels to less than 150 mmHg. Among the various 
classes of 
An Investigation on the Incidence and Prevalence of Drug related outcomes in Hypertensive 
Patients on ACE Inhibitors 
 
 
 26 
 
drugs, diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors, 
and angiotensin receptor blockers were proved beneficial in the elderly and are 
favored as first choices for the management of elderly hypertensive individuals. 
Given the common coexistence of other co morbidities and polypharmacy. The 
author also emphasizes that physicians should be careful when initiating or up 
titrating treatments to avoid potential adverse events or interaction with other drugs 
or diseases.29 
In the year 2016, Krogh Nielsen Tand his colleaguesperformed a case study 
on Life-threatening angio-oedema after the first dose of an ACE inhibitor but not an 
anaphylactic reaction.  A case of a 60-year-old Caucasian woman, with no prior 
history of swellings, who was admitted to a hospital due to life-threatening angio-
oedema. She had, the previous day, been prescribed an ACE inhibitor for her 
essential hypertension. She had taken one tablet at night-time, and awoke in the 
morning with a swollen face progressing to involve the tongue and throat within a few 
hours. On arrival at her doctor's office, her voice had altered. Corticosteroids and 
antihistamine were administered while awaiting an ambulance. Arriving at the 
emergency department, she had dyspnoea due to increasingly severe angio-oedema 
of the upper airways. Neither adrenaline inhalations, intravenously administrated 
corticosteroids, atropine nor furosemide were effective and the patient soon become 
bradycardiac. A tracheotomy was performed and the patient was placed on a 
ventilator. She eventually made a full recovery. It was concluded that she had 
suffered from life-threatening angio-oedema due to her new medication.30 
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In the year 2016,Simonyi G conducted a subgroup analysis of RAMONA 
Trial on Benefits of Fixed Dose Combination of Ramipril/Amlodipine in Hypertensive 
Diabetic Patients. 6423 patients completed the study. Among these patients, 1276 
(19.9%) patients suffered from type 2 diabetes mellitus. The mean age of these 
diabetic patients was 64.2 ± 10.0 years; 707 (55.4%) patients were males. Various 
fixed dose combinations of ramipril/Amlodipine were well tolerated and no adverse 
event related to the use of the medicine has appeared. The fixed dose combination 
of ramipril/Amlodipine was effective in hypertensive diabetic patients who failed to 
reach target BP previously.31 
In the year 2015,Rajavel Murugan R. and PadmavathiR. ConductedaStudy 
of Prevalence of Hyperuricaemia in Hypertension. The study was planned to assess 
the relation between hyperuricaemia and hypertension. In this study, 85 patients of 
new onset hypertension and the same number of patients attending NCD clinic were 
compared. Serum uric acid was measured in all the patients and data compared and 
analysed by unpaired t test. The mean value for both sexes was above normal and 
there was significant association between uric acid and hypertension especially in 
population of more than 45 years.32 
In the year 2015,Strassen U et al analysed a case series on angiotensin receptor 
blocker-induced angioedema and its management. The author presented a case 
series of patients admitted to their hospital due to angioedema induced by an 
Angiotensin II receptor blocker. The patients were either treated with either icatibant 
(n = 3) or prednisolone-21-hydrogen succinate/clemastine (n = 5). Both patient 
groups were compared with an untreated patient cohort (n = 3). All patients were 
previously diagnosed with essential hypertonic. Icatibant was an effective therapy for 
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angiotensin II receptor blocker-induced angioedema. Full symptom recovery was 
achieved after 5 to 7 hours, whereas symptom remission occurred within 27 to 52 
and 24 to 54 hours in patients treated with Solu-Decortin prednisolone/clemastine 
and untreated patients, respectively. Icatibant are a safe and effective substance for 
the treatment of angiotensin II receptor blocker-induced angioedema. Although the 
pathophysiology of angiotensin II receptor blocker-induced angioedema remains 
unclear, it appears to be associated with the bradykinin pathway.33 
In the year 2015, Fukuda SConducted a prospective study on frequency and 
characteristics of cough during ACE inhibitor treatment. Subjects in this study were 
176 patients overall (mean age 67 ± 11 years old), 90 men and 86 women. The 
adverse reaction of cough was observed in 20% of patients, and more frequently in 
women than in men. However, in 26 of the patients with cough, the cough either 
resolved naturally or completely disappeared while the treatment continued, after 
which patients could continue taking the medication. Specifically, ACE inhibitor 
treatment was eventually discontinued due to cough in 5.1% of patients. Cough 
occurred less frequently with concomitant calcium antagonists or diuretics than with 
ACE inhibitor monotherapy. Cough as an adverse reaction occurred at a low 
frequency when medication was taken at bedtime. They considered a number of 
measures to counteract cough, then in addition to starting the ACE inhibitor 
treatment as early as possible, it is important to devise ways for the ACE inhibitor 
treatment to be continued for as long as possible, through the adept use of these 
measures.34 
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In the year 2014, Loga Zec S et al performed a prospective study on the 
Incidence of Antihypertensive Drug-induced Side Effects in Patients with Diabetes 
Mellitus Type 2 and Hypertension.  They performed a prospective study of 79 
patients with DM type 2 and hypertension, randomly selected by systematic 
sampling, who were followed over a period of six months. Patients were assessed at 
baseline and once a month measuring following parameters: types of used 
antihypertensive drugs and frequency of side effects, the values (mmHg) of systolic 
(SBP) and diastolic blood pressure (DBP).Out of 79 patients, 60.8%were males and 
39.2%were females. The median age in males was 53 years, in females was 53 
years (IQR=49 to 56 years). The most common side effect was cough associated 
with the combination of ACE inhibitor and thiazide diuretics. In patients there were 
reports of flushing, palpitations, headache, dizziness and leg edema associated with 
Ca blockers. The most common side effect of antihypertensive treatment was cough 
associated with the combination of ACE inhibitor and thiazide diuretic.35 
In the year 2014, Mancia G et al conducted a study on Incidence of adverse 
events with telmisartan compared with ACE inhibitors. Incidence rates of adverse 
events for the combined ACE inhibitor treatments and for telmisartan were similar as 
were the rates of serious adverse events. Patients receiving ACE inhibitors had more 
cough with telmisartan. Results were similar irrespective of age, gender, or ethnicity. 
The adverse event of angioedema was observed in four patients receiving ACE 
inhibitors versus none with telmisartan .There were small, numerical differences in 
serious adverse events. A total of 107 patients (5.0%) receiving ACE inhibitors and 
93 patients (3.6%) receiving telmisartan discontinued treatment because of Adverse  
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Events. Telmisartan andACEinhibitorsproducedcomparable bloodpressurereductions 
at marketed doses. Telmisartan and ACE inhibitors are suitable for the prevention of 
cardiovascular events in high-risk patients, but telmisartan is better tolerated, 
particularly with regard to cough.36 
In the year 2014, Brugts JJand his colleagues conducted a prospective 
study on the incidence and clinical predictors of ACE-inhibitor induced dry cough by 
Perindopril in 27,492 patients with vascular disease. Multivariate logistic regression 
analysis was used to study the incidence of cough in relation to baseline clinical 
characteristics including racial background. A simple clinical risk score composed of 
these 3 predictors of cough mounted to an odds ratio of 4.4 in the subjects with 
highest score (i.e. all determinants present). This large combined analysis of 
randomized clinical trials in 27,492 patients showed an overall lower incidence 
of cough leading to discontinuation of ACE-inhibitors (3.9%) as compared to 
literature. Clinical determinants of such cough are older age, female gender and 
concomitant use of lipid-lowering agents. In contrast, racial differences were not 
related to the incidence of cough.37 
In the year 2014, Sidorenkov G and Navis G conducted a review on Safety 
of ACE inhibitor therapies in patients with chronic kidney disease. This paper reviews 
evidence from clinical studies regarding adverse effects of ACE inhibitors in patients 
with CKD. The safety aspects of ACE inhibitors are discussed in relation to their 
pharmacological action, drug-drug interactions, drug-diet interaction, and precautions 
needed in certain clinical conditions and other adverse effects. The main adverse 
effects of ACE inhibitors follow from their interaction with Renin-Angiotensin 
Aldosterone System (RAAS) activity and volume depletion. This interaction can be 
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turned into clinical benefit and increase efficacy of ACE inhibitors by reduction in 
dietary sodium or adding diuretics. The intensified treatment regimens based 
on ACE inhibitors can potentially improve renoprotection, but increase the risk of 
adverse effects. Better strategies to address safety concerns are needed. 
Introduction of clinical rules and safety indicators may help clinicians to identify 
hazardous co-prescriptions and adverse dietary habits and can decrease the 
frequency of adverse effects.38 
In the year 2014, Pinargote P et al performed a study on ACE inhibitors 
induced upper respiratory symptoms. Study concluded that Cough and angioedema 
are well-known adverse reactions of ACE inhibitors. However, other adverse effects 
of upper airways such as postnasal drainage, rhinitis and nasal blockage, are less 
frequently recognised. These might share the same pathophysiological mechanism: 
bradykinin accumulation. We present two patients with ACE inhibitor-induced upper 
respiratory symptoms that improved after the discontinuation of ACE-inhibitors and 
substitution with angiotensin II receptor blockers. The incidence of these adverse 
events is not accurately known, since these are not required to be reported, but it is 
estimated to be low. This presents challenges to the physician and demonstrates the 
importance of keeping it as a differential diagnosis. Most physicians are aware 
of ACE inhibitor-induced cough but not of ACE inhibitor-induced nasal blockage, 
rhinitis or postnasal drainage. Identifying these can avoid unnecessary diagnostic 
tests and inappropriate treatment.39 
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In the year 2013,Nishida Y et al conducted a retrospective observational 
study on Comparative effect of angiotensin II type I receptor blockers on serum uric 
acid in hypertensive patients with type 2 diabetes mellitus. In Losartan users, mean 
SUA level was significantly decreased from baseline, while it was conversely 
increased in users of other ARBs; valsartan, telmisartan, candesartan and 
olmesartan. The mean reduction of SUA level from baseline was significantly greater 
in Losartan users compared with that in other ARB users. Comparison of ARBs other 
than Losartan showed no significant difference in mean change in SUA level from 
baseline. The study results shows that Losartan had the most beneficial effect on 
SUA level among five ARBs, and that there was no significant difference in the 
unfavourable effects on SUA level among four ARBs other than Losartan, at least 
during one year. These findings provide evidence of an effect of ARBs on SUA level, 
and support the benefit of the use of Losartan in hypertensive patients with type 2 
DM. 40 
In the year 2013 , Heerspink  HJ et al performed a post-hoc analysis on the 
effect of ramipril and telmisartan on serum potassium and its association with 
cardiovascular and renal events .A post-hoc analysis of the ONTARGET trial 
comparing dual therapy (ramipril and telmisartan) vsmonotherapy (ramipril or 
telmisartan) was performed. The main cardiovascular outcome was the composite of 
cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure. 
The renal outcome was defined as the composite of a doubling of serum creatinine 
or chronic dialysis. The association was independent of age, gender, diabetes, 
estimated glomerular filtration rate, systolic blood pressure and diuretic use. With the 
Precautions stipulated by the protocol of the ONTARGET trial, hypokalemia and  
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hyperkalemia were infrequent events. Nevertheless, both high and low serum 
potassium were associated with an increased risk of cardiovascular and renal 
disease.41 
In the year 2012, Raebel MA conducted a review onHyperkalemia 
associated with use of angiotensin-converting enzyme inhibitors and angiotensin 
receptor blockers. Published incidence estimates of hyperkalemia associated with 
ACEi or ARB vary, but up to 10% of patients may experience at least mild 
hyperkalemia. Important Considerations when initiating ACEi or ARB therapy include 
obtaining an estimate of glomerular filtration rate and a baseline serum potassium 
concentration, as well as assessing whether the patient has excessive potassium 
intake from diet, supplements, or drugs that can also increase serum potassium. 
Serum potassium monitoring shortly after initiation of therapy can assist in 
preventing hyperkalemia. If hyperkalemia does develop, prompt recognition of 
cardiac dysrhythmias and effective treatment to antagonize the cardiac effects of 
potassium, redistribute potassium into cells, and remove excess potassium from the 
body is important. Understanding the mechanism of action of ACEi and ARB coupled 
with judicious drug use and clinical vigilance can minimize the risk to the patient of 
developing hyperkalemia.42 
In the year 2012, Cosentino M et al conducted a study onincreased 
reporting of adverse reactions to ACE inhibitors associated with limitations to drug 
reimbursement for angiotensin-II receptor antagonists. 228 reports of ACE inhibitor-
associated ADRs, and cough was the ADR reported in 93.4% of cases. There were 
no reports of cough in 2007, 50 in 2008, 156 in 2009 and 7 in 2010. In 2008-2009, 
the dispensation of ACE inhibitors showed little variation, while that of AT1 receptor  
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antagonists grew about twofold. There was a clear correlation between ACE 
inhibitor-associated ADR reporting and limitation to AT1 receptor antagonist 
reimbursement status. Drug reimbursement policies should thus be added to the list 
of factors that may bias ADR reporting, and health authorities should be aware of 
this potential bias when defining specific measures to regulate prescription and use 
of new drugs.43 
In the year 2012, Uday Venkat Mateti et alperformed a study on Pattern of 
Angiotensin-Converting Enzyme Inhibitors Induced Adverse Drug Reactions in South 
Indian Teaching Hospital. Their study was conducted to evaluate the incidence of 
ADRs due to angiotensin-converting enzyme Inhibitors in   cardiology    department.  
A cross-sectional observational study was carried out for a period of 6 months. 
Causality assessment showed that majority of ADRs was probable and were found 
to be moderately severe. The study concludes geriatrics and female patients have 
higher incidence of ADRs. So early identification and management of ADRs are 
essential for this population.44 
In the year 2012, Norman M Kaplanperformed a literature survey on Major 
side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor 
blockers. Side effects that occur with ACE inhibitors are related to either reduced 
angiotensin II formation or increased kinins. Those related to reduce angiotensin II 
formation include hypotension, acute renal failure, hyperkalemia and problems 
during pregnancy. Side effects thought to be related, at least in part, to increased 
kinins include cough, angioedema, and anaphylactic reactions. Hyperkalemia and 
renal failure may require termination of the ACE inhibitor. Treatment consists of  
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lowering the dose or discontinuing the drug. Readministration of the drug is 
associated with a high rate of recurrent cough .Angioedema is rare but potentially 
fatal complication of ACE inhibitors. Angioedema may also occur with ARBs but the 
risk is lower .Patients who are on both an ACE inhibitor and an ARB are at higher 
risk for adverse effects. Thus, combined therapy should not be considered in the 
treatment of hypertension or other disorders unless there is compelling evidence of 
benefit.45 
In the year 2010,Nishant V. Sangole and Vaishali N. Dadkar conducted a 
study on ADR monitoring with ACE inhibitor. One hundred and twenty patients with 
essential hypertension were randomized into four groups receiving Enalapril, 
Lisinopril, Ramipril, and Fosinopril. They were followed up for four months, to 
observe the clinical efficacy along with the associated ADRs.Mild, dry brassy cough 
(% incidence; 95% CI) was observed with d-ACEIs (6.6%; 0 to 15.6) versus p-ACEI 
(20%; 5.7 to 34.3), in which the cough observed was moderate-to-severe in intensity 
and two patients required treatment discontinuation (P <0.05).The authors concluded 
that the Phosphonate group in p-ACEIs may have a probable relationship with 
increase in the incidence and severity of ADRs such as dry brassy cough and 
hypotension. The di-carboxyl group in d-ACEIs may have a probable relationship 
with increase in the incidence of ADRs like nausea.46 
In the year 2008, Shibata MC et alConducted a systemic review on the 
effects of angiotensin-receptor blockers on mortality and morbidity in heart failure. 
Mortality data were available from 27,495 patients. The Author concluded that 
Angiotensin II receptor blockers did not show any beneficial effect on mortality when 
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used in combination with ACE-I or when compared with ACE-I alone. A 17% 
reduction in hospital admissions was observed.47 
In the year 2008, Matchar DB et al conducted a systemic review on 
comparative effectiveness of angiotensin-converting enzyme inhibitors and 
angiotensin II receptor blockers for treating essential hypertension. 61 clinical studies 
that directly compared ACE inhibitors versus ARBs in adult patients with essential 
hypertension were included. A standardized protocol with predefined criteria was 
used to extract data on study design, interventions, population characteristics, and 
outcomes; evaluate study quality and applicability; and assess the strength of the 
body of evidence for key outcomes.ACE inhibitors and ARBs had similar long-term 
effects on blood pressure (50 studies; strength of evidence, high). Consistent fair- to 
good-quality evidence showed that ACE inhibitors were associated with a greater 
risk for cough. There were fewer withdrawals due to adverse events and greater 
persistence with therapy for ARBs than for ACE inhibitors, although this evidence 
was not definitive. Available evidence shows that ACE inhibitors and ARBs have 
similar effects on blood pressure control, and that ACE inhibitors have higher rates of 
cough than ARBs. Data regarding other outcomes are limited.48 
In the year 2006, Overlack A performed a study on Incidence, mechanisms 
and management of ACE inhibitor-induced cough and bronchospasm. Cough has 
emerged as a class effect occurring with all ACE inhibitors with no clear difference 
between the single substances. While ACE inhibition is safe in the vast majority of  
patients with obstructive airways disease, asthmatic symptoms or exacerbation of 
asthma as well as a rise in bronchial reactivity have been occasionally reported. ACE 
inhibition increases the cough reflex. The mechanisms underlying ACE 
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inhibitorinduced cough are probably linked to suppression of kininase II activity, 
which may  
befollowed by an accumulation of kinins, substance P and prostaglandins. 
Physicians should be aware that a dry cough is the most common adverse effect of 
ACE inhibitors and that this symptom may occur not necessarily shortly 
afterinstitution of therapy but months or even a year later. Replacement by another 
ACE inhibitor should not be tried, since the cough will almost always recur on 
rechallenge with the same or another ACE inhibitor. After withdrawal of the ACE 
inhibitor, which is the treatment of choice, cough will resolve usually within a few 
days.49 
In the year 2004, Fogari Rand Zoppi A conducted a study on effect of 
antihypertensive agents on quality of life in the elderly. Calcium channel antagonists 
have generally been associated with a positive effect on quality of life, although 
some trials have shown high rates of adverse effects and withdrawals, particularly 
with first-generation dihydropyridines. They have been demonstrated not to interfere 
with or even improve cognitive function as well as sexual performance. Although no 
class of antihypertensive agents presents a clearly superior effect over the others in 
terms of quality of life, the current impression is that ACE inhibitors and angiotensin 
II receptor antagonists may offer some advantage, at least in regard to effects on 
cognitive function and sexual activity.50 
In the year 2002,Ahmed Aconducted a study to determine the association 
between the early rises in serum creatinine levels associated with the use of 
Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers 
(ARBs) and the long-term renoprotective properties of these drugs in patients with 
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chronic renal insufficiency. Patients with normal renal function were likely to show a 
much smaller rise in serum creatinine level (approximately 10% above the baseline 
of 0.9 mg/dL), mostly occurring during the first week after initiation of therapy, with 
subsequent stabilization, whereas patients with normal renal function suffering from 
heart failure, volume depletion, or bilateral renal artery stenosis experienced a 
significant rise (approximately 225% above baseline) in serum creatinine level. 
Patients with chronic renal insufficiency (serum creatinine>1.5 mg/dL) who received 
therapy with ACE inhibitors had about a five times higher risk of developing 
hyperkalemia than those with normal renal function, whereas presence of heart 
failure increased the risk of hyperkalemia by about three times over those without 
heart failure. The authors recommend that ACE inhibitor therapy should not be 
discontinued unless serum creatinine level rise above 30% over baseline during the 
first 2 months after initiation of therapy or hyperkalemia (serum potassium level 
>or=5.6 mmol/L) develops. 51 
In the year 2001, Alice Schmidt  et al conducted a prospective study on the 
effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric 
acid levels and potassium homeostasis in hypertensive renal transplant recipients 
treated with CsA. In this prospective, open, randomized, two‐way cross‐over study 
we included 13 hypertensive CsA‐treated patients after renal transplantation and 
administered either the angiotensin‐converting enzyme (ACE) inhibitors enalapril or 
Losartan. Serum aldosterone and urinary aldosterone excretion were significantly  
reduced only during ACE inhibitor treatment, which might explain the variable effects 
on potassium homeostasis. Losartan may be a useful agent to reduce blood 
pressure and serum uric acid levels in renal transplant recipients treated with CsA.  
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Furthermore, in this high‐risk population, the effects on serum potassium levels are 
less marked with Losartan than with enalapril.52 
In the year 1996, Kubota k. et al conducted a prescription event monitoring 
on cough induced by ACE inhibitor. Several factors which had obscured the causal 
relationship in the individual cases were found to be also an obstacle in PEM. For 
example, cough was a common and non-serious event and was under-reported in 
the PEM study of enalapril and the rate was not strikingly different from that recorded 
for other drugs. Cough induced by ACE-inhibitors has several characteristics which 
reduce the chance of a recognisable ‘signal’. The original questionnaires returned 
from doctors in the PEM study of enalapril have been re-examined. The observation 
that the rate of cough diminished after enalapril had been stopped rather than 
increased after starting, provided the best evidence of causality, because this was 
not affected by many biases such as the publicity that had occurred prior to doctors 
participating in PEM completed later reports.53 
In the year 1990, Moser M  conducted a prospective study on relative 
effectiveness and adverse reactions of Antihypertensive medications. It was found 
Thiazide diuretics may be more effective as antihypertensive agents in many subsets 
of patients than other medications, especially in reducing systolic blood pressure. 
Angiotensin converting enzyme (ACE) inhibitors and beta-blockers are less effective 
than calcium blockers or diuretics in black, beta-blockers may be less effective in the 
elderly. When used as initial monotherapy, most available antihypertensive drugs 
produce significant adverse subjective effects in about 8-10% of patients; centrally 
acting drugs, however, may produce annoying side effects in 20-30% of patients.  
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Diuretics are recommended as the second drug of choice if one of the other agents 
is used first. With this approach approximately 80% or more of patients can be 
controlled at normotensive levels on one or at most two drugs.54 
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3. AIM AND OBJECTIVES 
3.1. Aim  
The aim of the study wasto investigate the incidence and prevalence of drug related 
outcomes in hypertensive patients on ACE inhibitors. 
 
3.2. Objectives 
 
The objectives of the study were 
 
 To assessthe incidences of cardiac events in  patients with ACE inhibitor 
therapy  
 To assess the prevalence of liver diseases and hyperuricaemia in 
hypertensive patients with ACE inhibitors. 
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4. NEED FOR THE STUDY 
ACE inhibitors are the first choice of drugs in all grades of essential as well as 
renovascular hypertension. Although many research have been done so far to 
assess the antihypertensive efficacy of ACE inhibitors they have serious adverse 
effects related to it like angioedema, hypotension, hyperkalaemia, sleep 
disturbances, hyperuricaemia, cough, rashes, urticaria etc.  
Many epidemiological studies and supportive literature states that these ACE 
Inhibitors induced adverse events are one of the important reasons for persistent 
morbidity and mortality in developed countries. But in developing countries like India 
the reported cases of incidence of drug related side effects due to ACE inhibitors are 
less compared that of developed countries. But studies shows that, since much 
hypertensive patients are in India the actual incidence of specific adverse events in 
hypertension goes unreported and the actual epidemiology in India is not well 
understood. 
We designed this study in an attempt to understand the incidence of cardiac events 
and prevalence of hyperuricaemia and liver diseases in hypertensive patients on 
ACE inhibitorswhich were expected to be reported among rural population ata 
multispecialty hospital in Namakkal district.  
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5. SCOPE OF THE STUDY 
The study was conducted enrolling all the male and female patients strictly on 
the basis of underlying disease (i.e.) hypertension, age and medication prescribed 
with ACE inhibitors. So we expect the results to be unbiased and confounding. 
The study was expected to give clear report on the incidence of cardiac 
events, and prevalence of hyperuricaemia and liver disease since it was conducted 
in hospital located in rural region as we expect the results to be more reliable, 
repeatable and reproducible. 
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                                                    6. PLAN OF WORK 
The proposed study entitled “An investigation on the incidenceand prevalence of 
drug related outcomes in hypertensive patients under ACE inhibitor therapy”was 
planned and carried out in a tertiary care hospital as given below. 
 
Phase I 
 Identification of research problem and scope of the study 
 Literature survey 
 Preparation of study protocol 
 Obtaining ethical clearance from the hospital authorities  
Phase II 
 Design of structured pro-forma  
 Patient selection  
 Obtaining patient consent  
 Data retrieval from the cardiology and general medicine 
department.  
Phase III 
 Data analysis  
 Report submission  
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7. METHODOLOGY 
7.1 STUDY DESIGN 
Prospective observational study 
 7.2 STUDY CENTRE 
Department of General medicine and cardiology inVivekananda Medical Care     
Hospital, Tiruchengodu. 
 7.3 STUDY DURATION 
July 2016 – June 2017 (12months) 
 
 7.4 ETHICAL COMMITTEE APPROVAL 
The study protocol was approved by the institutional ethics committee of 
Vivekanandha Medical Care Hospital (Ref.No:SVCP/IEC/JAN/2016/13) 
(Annexure – 1) 
 7.5 SAMPLE POPULATION 
Total 230 patients who are having hypertension and under ACE inhibitor 
therapy were screened and 112 records were selected based on the following 
inclusion and exclusion criteria for further study. 
7.6 INCLUSION CRITERIA 
 Patients of both the genders of more than 18years in age  
 Patients with Hypertension prescribed with ACE inhibitors 
 Both in and out patients 
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7.7 EXCLUSION CRITERIA 
 Patients who are not willing to participate in the study  
 Pregnant and Lactating females 
 Patients with insufficient data in their records 
 
7.8 DATA COLLECTION 
Consent was obtained from each subject in Patient Consent form before 
initiating the study. Structured pro-forma was used to collect various clinical and 
demographic details of the patients such as age, gender, reason for admission, past 
medical history, past medication history, vital signs, lab investigations, primary 
diagnosis and treatment chart. Treatment data including prescribed drugs, doses, 
frequency and route of administration were also recorded.  
7.9 METHOD 
Patients were assessed at baseline with respect to age, gender, BMI, co-
morbidity conditions, ACE inhibitors prescribed and duration of therapy. Patient was 
followed up for 6 months. The incidences of cardiac events wereidentified and 
prevalence of hyperuricaemia and liver diseases wereanalysed. 
7.11 STATISTICS  
The statistical analysis was done using Microsoft excel. All the datas were expressed 
in percentage. Collected data’s were entered in Microsoft excel spreadsheet for 
further interpretations. 
 
An Investigation on the Incidence and prevalence of drug related outcomes in Hypertensive 
Patients on ACE Inhibitors 
 
 
 
 47 
 
                                                 8. RESULTS 
A total of 230 patients who are having hypertension and taking ACE inhibitors 
in cardiology and general medicine department were screened and 112 records were 
selected based on the inclusion and exclusion criteria. 
 
8.1. AGE WISE DISTRIBUTION OF THE STUDY POPULATION 
Out of 112 cases, 2.7% (3) were in the age group of 20-29 years, 15.1.% (17) 
were in the age group of 30-39 years, 27.7% (31) were in the age group of 40-49 
years, 37.5% (42) were in the age group of 50-59 years, 8% (9) were in the age 
group of 60-69 years and 9% (10) were in the age group of 70-79 years. Mean age 
of the study population was 55.7 ± 6years. (Table 1, Figure 1) 
 
Table 1. Age wise distribution of the study  population   (n=112) 
 
S.No. 
 
 
 
Age (years) 
 
 
No of Patients 
 
Percentage(%) 
1.  20-29 3 2.7 % 
2.  30-39 17 15.1% 
3.  40-49 31 27.7% 
4.  50-59 42 37.5% 
5.  60-69 9 8% 
6.  70-79 10 9% 
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Figure 1. Age Wise distribution of the study  population   (n=112) 
 
 
 
 
8.2 GENDER WISE DISTRIBUTION AMONG THE STUDY POPULATION 
A total of 112 hypertensive patients, males were 61.6% (69) and females were  
38.39% (43). (Table 2, Figure 2) 
 
Table 2. Gender wise distribution of the study population (n=112) 
 
Gender 
 
Number of Patients 
 
Percentage 
 
Male 
 
69 
 
61.6 % 
 
Female 
 
43 
 
38.4 % 
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Figure 2. Gender wise distribution among the study population (n=112) 
 
 
8.3. BODY MASS INDEX OF THE STUDY POPULATION 
A total   of 112 patients, 8%  (9 were in normal body weight, 14.9% (16)  were Under 
Weight, 65.1% (74) were overweight and 12% (13) were Obese. (Table 3,  Figure 3) 
 
Table 3. BMI among the study population (n=112) 
 
BMI Number of Patients Percentage 
Underweight 9 8% 
Normal 16 14.9% 
Overweight 74 65.1% 
Obese 13 12% 
 
 
 
 
 
61.60% 
38.40% 
Male
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Figure  3. BMI among the study population   (n=112) 
 
                           
 
8.4. SOCIAL HABITS OF THE STUDY POPULATION 
Out of 112 patients, 27.7% (31) were smokers and 72.3% (81) were non smokers. 
 (Table 4, Figure 4) 
Table  4. History of smoking among the study population    (n=112) 
 
 
Smoking habits 
 
Number of Patients 
 
Percentage 
 
Smokers 
 
31 
 
27.7% 
 
Non-smokers 
 
81 
 
72.3% 
             
8% 
15% 
65% 
12% 
Underweight Normal Overweight Obese
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Figure  4. History of smoking among the study population    (n=112) 
 
             
 
Out of 112 patients, 23.2% (26) were alcoholic and 76.8% (86) were non alcoholic,  
(Table 5, Figure 5) 
 
Table  5. History of alcoholism among the study population    (n=112) 
 
 
Alcoholic habits 
 
Number of Patients 
 
Percentage 
 
Alcoholic 
 
26 
 
23.2% 
 
Non-alcoholic 
 
86 
 
76.8% 
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72.30% 
Smokers
Non-smokers
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Figure  5. History of alcoholism among the study population    (n=112) 
 
                         
8.6. DURATION OF HYPERTENSION AMONG THE STUDY POPULATION  
    A total of 112 patients, 51.07% (59) were having 1 year duration of 
Hypertension, 12.1% (13 ) were having 2-4 years duration of Hypertension, 18.01% 
(20) were having 5-10 years duration of hypertension, 18.01% (20) were having  10-
15  years duration of Hypertension (Table 6,figure 6) 
 
Table  6. Duration of hypertension among the study population (n=112) 
 
Duration of Hypertension 
 
Number of Patients 
 
Percentage 
1 year 59 51.07% 
                  2-4 years 13 12.1% 
                 5- 10 years 20 18.01% 
10-15  years 20 18.01% 
 
23.20% 
76.80% 
Alcoholic
Non-alcoholic
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Figure 6. Duration of hypertension among the study population   (n=112) 
 
            
 
8.7. PATTERN OF PREVALENCE OF CO-MORBIDITIES AMONG THE STUDY 
POPULATION  
 A total of 112 patients, 83.1% (93) were having hypertension alone, 9.8% (11) were 
hypertension with diabetes mellitus, and 7.14% (8) have hypertension with other 
complications. (Table 7, figure 7) 
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Table  7. Pattern of co-morbidities prevalence among the study population 
(n=112) 
 
 
Figure 7. Pattern of co-morbidities prevalence among the study population   
(n=112) 
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8.8. ACE INHIBITORS PRESCRIBED IN THE STUDY POPULATION 
A total of 112 patients, 6.6% (7) prescribed with captopril, 20.53% (23 
patients) prescribed with enalapril, 54.46 %( 61) prescribed with Ramipril, 12.5% 
prescribed with (14) prescribed with Perindopril and 6.25% (7) prescribed with 
Lisinopril. (Table 8, Figure 8) 
 
Table  8. Ace inhibitors prescribed in the study population (n=112) 
 
 
 
S. No 
 
ACE 
Inhibitors 
prescribed 
 
 
Dose 
 
 
Frequency 
 
Number of     
  Patients 
 
 
Percentage 
1. Captopril 50mg TD 7 6.6% 
2. Enalapril 10mg OD 23 20.53% 
 
      3. 
 
Ramipril 
      
    1.25mg 
 
OD 
 
61 
 
54.46% 
     2.5 mg 
4. Perindopril 20mg OD 14 12.5% 
5. Lisinopril 40mg OD 7 6.25% 
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Figure  8. ACE inhibitors prescribed in the study population (n=112) 
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8.9. ASSESSMENT OF INCIDENCE OF CARDIAC EVENTS IN THE STUDY 
POPULATION 
Out of 112 patients incidence of cardiac events found in Hypertensive patients who 
are under ACE inhibitors were 23, in which 10.71% (12) had myocardial infarction 
and 9.82% (11) had Angina pectoris. (Table 9, Figure 9) 
 
Table 9. Incidence of cardiac events in the study population (n=112) 
Cardiac events No. of patients Percentage (%) 
Myocardial infarction 12 10.71% 
Angina pectoris 11                9.82% 
Total 23 100 % 
 
Figure 9. Incidence of cardiac events in the study population (n=112)  
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8.10. INCIDENCE OF MYOCARDIAL INFARCTION 
Among 12 patients with incidence of myocardial infarction 2.6% (3) were having 
STEMI and 8.1 % (9) were having NSTEMI. (Table 10, Figure 10) 
 
Table 10. Incidence of myocardial infarction based on type (n=112) 
 
Myocardial infarction 
 
No. of patients 
 
Percentage (%) 
STEMI 3 2.6% 
NSTEMI 9 8.1% 
 
Figure 10. Incidence of myocardial infarction based on type (n=112) 
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8.11. INCIDENCE OF MYOCARDIAL INFARCTION IN PATIENTS ON ACE 
INHIBITORS 
Out of 12 patients with incidence of MI with ACE inhibitors 0.9% (1) prescribed with 
Captopril, 2.6% (3) with Enalapril, 6.3% (7) with Ramipril, 0.8% (1) with Perindopril. 
(Table 11, Figure 11)   
 
Table 11. Incidence of Myocardial Infarction in Patients on ACE Inhibitors 
(n=112) 
 
 
 
S. no. 
 
ACE Inhibitors 
prescribed 
 
 
Dose 
 
 
Frequency 
 
 Number of    
   Patients 
 
Percentage 
1 Captopril 50mg TD 1 0.9 % 
2 Enalapril 10mg OD 3 2.6% 
 
        
      3 
 
 
Ramipril 
     
    1.25mg 
 
 
OD 
 
3 
 
2.6% 
 
    2.5 mg 
 
4 
 
3.6% 
4 Perindopril 20mg OD 1 0.8% 
5 Lisinopril 40mg OD 0 0% 
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Figure 11. Incidence of Myocardial Infarction in patients on  ACE inhibitors 
(n=112) 
       
 
8.12. INCIDENCE OF ANGINA PECTORIS BASED ON TYPE 
Among 112 patients in the study population 11 patients were having Angina pectoris 
in which 2.6% (3) are having stable angina, 5.4% (6) were having unstable Angina, 
1.7% (2) having micro vascular angina. (Table12, Figure12) 
Table 12. Incidence of Angina Pectoris based on Type 
 
Cardiac events 
 
No. of patients 
 
Percentage (%) 
Stable Angina 3 2.6 % 
Unstable Angina 6 5.4% 
Micro-vascular angina 2 1.7% 
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Figure 12.  Incidence of Angina pectoris based on Type 
 
 
8.13. INCIDENCE OF ANGINA PECTORIS IN PATIENTS ON ACE INHIBITORS  
Among 11 patients, Incidence of Angina pectoris on ACE inhibitors 1.7% (2patients) 
prescribed with Captopril, 0.8% (1) with Enalapril, 4.4% (5) with Ramipril, 2.6% (3) 
with Perindopril and 0.8% (1) with Lisinopril. (Table 13, Figure 13) 
 
 
 
 
2.6 % 
5.4 % 
1.7 % 
0 1 2 3 4 5 6
Stable Angina
Unstable Angina
Micro-vascular angina
Percentage (%) 
An Investigation on the Incidence and prevalence of drug related outcomes in Hypertensive 
Patients on ACE Inhibitors 
 
 
 
 62 
 
Table 13.  Incidence of Angina Pectoris in patients on  ACE inhibitors (n=112) 
 
 
S. No. 
 
ACE Inhibitors 
prescribed 
 
      Dose 
 
Frequency 
 
Number of 
Patients 
 
Percentage 
(%) 
1. Captopril 50mg TD 2 1.7 % 
2. Enalapril 10mg OD 1 0.8% 
 
 
3. 
 
 
Ramipril 
 
 
1.25mg 
 
 
 
 
OD 
 
 
3 
 
 
2.6% 
 
2.5 mg 
 
2 
 
1.7% 
4. Perindopril 20mg OD 3 2.6% 
5. Lisinopril 40mg OD 1 0.8% 
 
Figure 13. Incidence of Angina pectoris in patients on ACE inhibitors (n=112) 
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8.14. ASSESSMENT OF PREVALENCE OF LIVER DISEASES 
Out of 112 patients prevalence of liver diseases on ACE inhibitors were found in 5 in 
which 2.6% (3) are having jaundice and 1.7% (2) are having hepatitis (Table 14, 
Figure 14) 
Table 14. Prevalence of liver diseases 
 
Liver diseases 
 
No. of patients with 
prevalence 
 
Percentage (%) 
Jaundice 3 2.6 % 
Hepatitis 2 1.7% 
 
Figure 14. Prevalence of Liver diseases 
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8.15. PREVALENCE OF LIVER DISEASES BASED ON GENDER 
Among 5 patients having prevalence of liver diseases, 3.5% (4) are male and 0.9% 
(1) was female. (Table 15, Figure 15) 
 
Table 15.  Prevalence of Liver diseases based on Gender (n=112) 
 
Gender 
No. of patients with 
prevalence 
 
Percentage (%) 
male 4 3.5 % 
female 1 0.9% 
 
 
Figure 15 -Prevalence of Liver diseases based on Gender (n=112) 
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8.16. PREVALENCE OF LIVER DISEASES BASED ON SOCIAL HISTORY 
Among 5 patients having prevalence of liver diseases 1.7% (2) were smokers and 
2.6% (3) were non smokers, 3.5% (4) were alcoholic and 0.9% (1) was non 
alcoholic. (Table 16, Figure 16) 
Table 16. Prevalence of liver diseases based on social history (n=112) 
 
Social history 
No. of patients with 
prevalence 
 
Percentage (%) 
Smoker 2 1.7% 
Non Smoker 3 2.6% 
Alcoholic 4 3.5% 
Non Alcoholic 1 0.9% 
 
Figure 16. Prevalence of liver diseases based on social history (n=112) 
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8.17. PREVALENCE OF   LIVER DISEASES IN HYPERTENSIVE PATIENTS ON 
ACE INHIBITORS  
Among 5 patients with prevalence of Liver diseases with ACE inhibitors, 0.9% (1) 
prescribed with Enalapril, 0.9% (1) with Ramipril, 2.6% (3) with Lisinopril. (Table 17, 
Figure 17) 
 
Table 17.  Prevalence of   liver diseases in patients on ACE inhibitors (n=112) 
 
S. No. 
 
ACE Inhibitors 
prescribed 
 
Dose 
 
Frequency 
 
Number of   
Patients 
 
Percentage 
      (%) 
1 Captopril 50mg TD 0 0 % 
2 Enalapril 10mg OD 1 0.9% 
 
 
3 
 
 
       Ramipril 
 
1.25mg 
 
 
OD 
 
1 
 
0.9% 
 
2.5 mg 
 
0 
 
0% 
4 Perindopril 20mg OD 0 0% 
5 Lisinopril 40mg OD 3 2.6% 
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Figure  17. Prevalence of   liver diseases in patients on ACE inhibitors (n=112) 
 
 
8.18. ASSESSMENT OF PREVALENCE OF HYPERURICAEMIA 
Among 112 patients prevalence of hyperuricaemia was present in 20. (Table 18 
Figure 18) 
Table 18. Prevalence of Hyperuricaemia 
 
Hyperuricaemia 
 
No. of patients with 
prevalence 
 
Percentage (%) 
Present 20   17.85 % 
Absent 92 82.15 % 
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Figure 18. Prevalence of hyperuricaemia 
 
                   
 
8.19. PREVALENCE OF HYPERURICAEMIA BASED ON GENDER 
Among 20 patients having prevalence of hyperuricaemia, 6.25% (7) are male and 
11.6% (13) are female. (Table 19, Figure 19) 
 
Table 19. Prevalence of hyperuricaemia based on gender (n=112) 
 
Gender 
 
No. of patients with 
prevalence 
 
Percentage (%) 
 
Male 
 
7 
 
6.25 % 
 
Female 
 
13 
 
11.6% 
 
17.85 % 
82.15 % 
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Figure 19. Prevalence of hyperuricaemia based on gender (n=112) 
                
 
  
 8.20. PREVALENCE OF HYPERURICAEMIA BASED ON SOCIAL HISTORY 
Out of 20 patients having prevalence of hyperuricaemia 2.6% (3) are smokers and 
15.1% (17) are non smokers, 1.8 % (2) are alcoholic and 16.1 % (18) are non 
alcoholic. (Table 20, Figure 20) 
 
    Table 20. Prevalence of hyperuricaemia based on social history (n=112) 
Social history No. of patients with 
prevalence 
Percentage (%) 
Smoker 3 2.6 % 
Non smoker 17 15.1% 
alcoholic 2 1.8% 
Non alcoholic 18 16.1% 
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Figure  20. Prevalence of hyperuricaemia based on social history (n=112) 
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Out of 20 patients with prevalence of Hyperuricaemia on  ACE inhibitors, 3.5% (4) 
prescribed with Captopril, 1.7% (2) prescribed with Enalapril, 2.6% (3) with Ramipril, 
0.9% (1) with Perindopril. 1.7 %( 2) with Lisinopril. (Table 21, Figure 21) 
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Table 21. Prevalence of Hyperuricaemia in patients on  ACE Inhibitors (n=112) 
 
  S. no. 
 
ACE Inhibitors 
prescribed 
 
Dose 
 
Frequency 
 
Number of      
  Patients 
 
Percentage 
       (%) 
1 Captopril 50mg TD 4 3.5% 
2 Enalapril 10mg OD 2 1.7% 
 
 
3 
 
 
Ramipril 
 
1.25mg 
 
 
OD 
 
1 
 
0.9% 
 
2.5 mg 
 
2 
 
1.7% 
4 Perindopril 20mg OD 1 0.9% 
5 Lisinopril 40mg OD 2 1.7% 
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Figure 21.  Prevalence of Hyperuricaemia in patients on ACE Inhibitors 
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9. DISCUSSION 
 Hypertension is a leading risk factor affecting mortality and disability-adjusted life 
years worldwide.55 It is considered to be the third major cause of disease burden, 
globally.57 Regardless of the advancement in medical science, reports have shown a 
rising trend in hypertension prevalence among Indians.58,59 
It is a chronic disorder, so long term intake of medicine is necessary to control 
elevated blood pressure. Long term usage of drugs may have adverse impacts on 
patients health and quality of life.  
This study specifically tried to find out the Incidence of Cardiac Events and 
Prevalence of Hyperuricaemia and Liver Diseases in Hypertensive Patients on ACE 
Inhibitors. 
The total outcome of the study was clear and demonstrative. This study 
comprised of 112 patients, out of which, most patients were in the age group of 50-59 
years Mean age of the study population was 55.7 ± 6years. In this study, the male 
patients 61% were more predominant in number than the female patients 39%. A study 
conducted by Aslam et al. showed the patients were in the age group of 50-59 years 
with regard to gender distribution, 59.7% were males.24 
 A study conducted by Hallberg p et al. shows that most of the patients were 
having normal body mass index. In present study majority of the patients were 
overweight.2   
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Out of 112 patients, non smokers and non alcoholic were more exposed to drug 
related outcomes than smokers and alcoholics.  
A total of 112 patients, 51.07% (59) were having 1year duration of Hypertension, 
12.1% (13) were having 2-4years duration of Hypertension, 18.01% (20) were having 5-
10 years duration of hypertension, and 18.01% (20) were having 10-15 years duration 
of Hypertension.  (Table 6, Figure 6).  
The co-morbidities like diabetes mellitus and other complications co-exist with 
hypertension. But patients with no co-morbidity other than hypertension are more 
predominant in my study. (Table 7, figure 7)  
A total of 112 patients, 6.6% (7) prescribed with captopril, 20.53% (23) 
prescribed with enalapril, 54.46% prescribed with ramipril, 12.5% prescribed with (14) 
prescribed with Perindopril and 6.25% (7) prescribed with Lisinopril. (Table 8, Figure 8) 
This shows that ramipril is the most prescribed drug in the study population. 
Incidence of Cardiac Events 
The incidence of cardiac events in hypertensive patients with ACE inhibitors were 
found to be 20.53% which is supporting the study results of Bo Haberg et al which were 
27.9% respectively. Our study also shows that the incidence of Angina pectoris and 
Myocardial infarction were predominant among cardiac events which were 10.71 % and 
9.8% respectively. Males were more prone to the incidences of Angina and myocardial 
infarction. The drugs which cause maximum number in incidences of cardiac events 
were Ramipril 6%.   
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Prevalence of Liver diseases 
Among 112 patients prevalence of liver diseases due to ACE inhibitors were 5 in which 
2.6% (3) had jaundice and 1.7% (2) had hepatitis. (Table 14, Figure 14) 
In our study Social history shows among 5 patients having prevalence of liver 
diseases 1.7% (2) are smokers and 2.6% (3) are non smokers, 3.5% (4) were alcoholic  
and 0.9% (1) is non alcoholic which clearly demonstrates alcoholics are more prone to 
incidences of liver diseases. (Table 16, Figure 16) 
  Among 5 patients having prevalence of liver diseases, 4 were male and 1 was 
female. (Table 15, Figure 15). Out of 5 patients, prevalence of Liver diseases with ACE 
inhibitors Lisinopril shows more incidences. (Table 17, Figure 17) 
Prevalence of Hyperuricaemia  
In our study we observed that 17.85% of patients with hypertension had 
hyperuricaemia which is in line with the study of Assob et al, his study showed that 33% 
of total population had a high (UA) concentration, with 49.5% being hypertensive. 
Our study results also show that females are more prone to hyperuricaemia than 
male patients with hypertension. (Table 19, Figure 19)  
Out of 20 patients having prevalence of hyperuricaemia 2.6% (3 patients) are 
smokers and 15.1% (17) are non smokers, 1.8 % (2) were alcoholic and 16.1 % (18 
patients) were non alcoholic which clearly demonstrates that the subjects with 
incidences were non smokers and non alcoholics. (Table 20, Figure 20) 
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In our study, 20 patients with prevalence of Hyperuricaemia due to ACE inhibitors 
3.5% (4) prescribed with Captopril, 1.7% (2 patients) prescribed with Enalapril, 2.6% (3) 
with Ramipril, 60.7%, 0.9% (1) with Perindopril. 1.7% (2) with Lisinopril. This shows 
captopril shows higher incidences of hyperuricaemia. (Table 21, Figure 21) 
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10. CONCLUSION 
The incidence of Cardiac events like Angina pectoris and myocardial infarction in 
males were much higher than in females. This indicates that hospitalization of cardiac 
events for males has increased who were in the age group of 50-59. 
Patients who are overweight according to BMI are having the highest risk of 
cardiac events. Moderate exercises can be recommended to the patients so that the 
incidence of cardiac events can be possibly reduced. 
Patients prescribed with ramipril are having higher incidence of cardiac events 
among all the ACE inhibitors prescribed. So the pharmacist should actively participate 
and intervene to reduce the incidences and recommend alternate drug therapy to the 
physician with aid of evidence based literatures. 
The prevalence of liver diseases and hyperuricaemia were low when compared 
to that of incidences in cardiac events. 
The prevalence of liver diseases like jaundice and hepatitis were more in male 
population and also predominant with alcoholics .The drug Lisinopril shows more 
incidences when compared to other ACE inhibitors so alternative therapy along with 
effective dosage regimen should be recommended. 
 The prevalence of hyperuricaemia in patients with ACE inhibitors was higher with 
females.BMI profile of the patients also has considerable effect over the prevalence of 
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hyperuricaemia and the drug captopril causes higher number of incidences of 
hyperuricaemia. 
 As per the findings, Incidences of Drug induced problems are common in a 
hospital and some of them results in increased healthcare cost due to the need of 
intervention and increased length of hospital stay. Early identification and early initiation 
and early recovery help to avoid complications hence knowledge about the drug related 
outcomes are essential to avoid drug related problems. Active involvement of well 
trained clinical pharmacist for assessing the incidences and prevalence and creating 
awareness in health care professionals and patients, regarding to need of reporting the 
incidence could improve the scenario under reported hospital. 
 In present study we have documented the incidences and prevalence of drug 
related outcomes in hypertensive patients with ACE inhibitors thereby increasing 
awareness among health care professionals. 
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11. LIMITATIONS 
 
 Most of the incidences were left unreported which may be attributed to the 
lack of awareness among nurses and attitude of health care professionals. 
 Limitation of sample size. 
 Incidence rate obtained of ADRs in Patient setting represents a skewed image 
of the true incidence, which is often difficult to estimate. 
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12. FUTURE OUTLOOK 
 
 To strengthen reporting of incidences and prevalence of drug related 
outcomes in patients, nurses, physician and other health care professionals 
by improving awareness and education program in hospital. 
 To extend the project to a large population in community settings by providing 
training to working community pharmacist’s to encourage them in reporting 
and monitoring of incidences. 
 To assess the risk factors associated with the incidences. 
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Swamy Vivekanandha College of Pharmacy, Elayampalayam 
Institutional Ethics Committee 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS 
(Strike off items that are not applicable) 
 
I / We (write name of the investigator(s) here),                                                               am / are carrying 
out a study on the topic:                                                                                 as part of my / our research 
project being carried out under the aegis of the Department of:  
(Applicable to students only): My / our research guide is:  
The justification for this study is:  
The objectives of this study are:  
Primary Objective:  
Secondary Objective:  
Sample size:  
Study volunteers / participants are (specify population group & age group):  
Location:  
We request you to kindly cooperate with us in this study. We propose collect background information 
and other relevant details related to this study. We will be carrying out:  
Initial interview (specify approximate duration):  
Data collected will be stored for a period of     years. We will / will not use the data as part of another 
study. 
Health education sessions: Number of sessions: 1.Approximate duration of each session:  
Clinical examination (Specify details and purpose):  
Blood sample collection: Specify quantity of blood being drawn:  No. of times it will be collected:  
Whether blood sample collection is part of routine procedure or for research (study) purpose:   
1. Routine procedure 2. Research purpose  
Specify purpose, discomfort likely to be felt and side effects, if any:  
Whether blood sample collected will be stored after study period: Yes / No, it will be destroyed 
Whether blood sample collected will be sold: Yes / No  
Whether blood sample collected will be shared with persons from another institution: Yes / No 
Medication given, if any, duration, side effects, purpose, benefits:  
Whether medication given is part of routine procedure: Yes / No (If not, state reasons for giving this 
medication) 
  
Whether alternatives are available for medication given: Yes / No (If not, state reasons for giving this 
particular medication) 
Final interview (specify approximate duration): NA If photograph is taken, purpose:  
Benefits from this study:   
Risks involved by participating in this study:  
How the results will be used:  
If you are uncomfortable in answering any of our questions during the course of the interview / 
biological sample collection, you have the right to withdraw from the interview / study at anytime. 
You have the freedom to withdraw from the study at any point of time. Kindly be assured that your 
refusal to participate or withdrawal at any stage, if you so decide, will not result in any form of 
compromise or discrimination in the services offered nor would it attract any penalty. You will continue 
to have access to the regular services offered to a patient. You will NOT be paid any remuneration for 
the time you spend with us for this interview / study. The information provided by you will be kept in 
strict confidence. Under no circumstances shall we reveal the identity of the respondent or their families 
to anyone. The information that we collect shall be used for approved research purposes only. You will 
be informed about any significant new findings - including adverse events, if any, – whether directly 
related to you or to other participants of this study, developed during the course of this research which 
may relate to your willingness to continue participation. 
Consent: The above information regarding the study, has been read by me/ read to me, and has been 
explained to me by the investigator/s. Having understood the same, I hereby give my consent to them 
to interview me. I am affixing my signature / left thumb impression to indicate my consent and 
willingness to participate in this study (i.e., willingly abide by the project requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal Representative:  
 
 
 
Signature of the Interviewer with date:      Witness: 
Xg;Gjy; gbtk; 
Njjp:  
 
--------------------------------------------------------- Mfpa ehd;> VMCH kUj;Jtkidapy; -----
-------------------------------------------------------------- Jiwapd; fPo;> -----------------
--------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------vd;w 
jiyg;gpy; Ma;T Nkw;nfhs;s cs;Nsd;. 
 
vd; Ma;T topfhl;b: 
 
Ma;T Nkw;nfhs;tjw;fhd mbg;gil: 
 
 
Ma;tpd; Nehf;fk;: 
 
 
Ma;T Nkw;nfhs;Sk; ,lk;: 
 
Ma;tpd; gyd;fs;: 
 
 ,e;j Ma;tpy; fpilf;Fk; jfty;fs; -------------- tUlq;fs; ghJfhf;fg;gLk;.  ,it NtW 
ve;j Ma;tpw;Fk; gad;gLj;jg; gl khl;lhJ.  ve;j epiyapYk; cq;fisg; gw;wpa jfty;fs; 
ahUf;Fk; njhptpf;fg;gl khl;lhJ.  mit ,ufrpakhf itf;fg;gLk;. 
 ,e;j Ma;tpy; gq;Nfw;f xg;Gf;nfhs;Stjhy; ve;j tpjkhd gyDk; cq;fSf;Ff; 
fpilf;fhJ.  ve;j Neuj;jpy; Ntz;LkhdhYk; Ma;tpypUe;J tpyfpf; nfhs;Sk; chpik 
cq;fSf;F cz;L. 
 Ma;tpypUe;J tpyfpf;nfhs;tjhy; cq;fSf;F mspf;fg;gLk; rpfpr;irapy; ve;j tpj 
khw;wKk; ,Uf;fhJ. 
 ,e;j Muha;r;rpf;fhf cq;fsplk; rpy Nfs;tpfs; Nfl;fg;gLk; / rpy ,uj;j khjphpfs; 
my;yJ jpR khjphpfs; vLf;fg;gLk;. 
 NkYk;> ,e;j Ma;tpy; gq;F nfhs;tJ cq;fs; nrhe;j tpUg;gk;.  ,jpy; ve;j tpjf; 
fl;lhaKk; ,y;iy.  ePq;fs; tpUg;gg;gl;lhy;> ,e;j Ma;tpd; KbTfs; cq;fSf;Fj; 
njhpag;gLj;jg;gLk;. 
 
Ma;thshpd; ifnahg;gk; : 
 
Njjp    : 
 
Ma;Tf;Fl;gLgthpd; xg;Gjy;: 
 
 ehd; ,e;j Muha;r;rpapd; Nehf;fk; kw;Wk; mjd; gad;ghl;bidg; gw;wp 
njspthfTk;> tpsf;fkhfTk; njhpag;gLj;jg; gl;Ls;Nsd;.  ,e;j Muha;r;rpapy; gq;F 
nfhs;sTk;> ,e;j Muha;r;rpapd; kUj;Jt uPjpahd Fwpg;Gfis tUk; fhyj;jpYk; 
cgNahfg;gLj;jpf; nfhs;sTk; KO kdJld; rk;kjpf;fpNwd;. 
 
Ma;Tf;Fl;gLgthpd; ngah;> Kfthp : 
 
 
    ifnahg;gk; : 
 
    Njjp  : 
DATA ENTRY FORM 
 
NAME OF PATIENT:      IP NO.            DEPARTMENT DOA DOD 
AGE/SEX HEIGHT 
(cm) 
WEIGHT 
(kg) 
     BMI FAMILY HISTORY: OCCUPATION 
    
COMPLAINTS ON ADMISSION: 
MEDICAL HISTORY: MEDICATION HISTORY: 
SOCIAL HISTORY KNOWN ALLERGIES: 
ALCOHOLIC SMOKER TOBACCO OTHERS 
 
VITAL SIGNS (PROGRESS CHART) 
PARAMETERS DAY 1 DAY 2 DAY 3 DAY 4 DAY 5 DAY 6   DAY 7 DAY 8 DAY 9  DAY 10 
BP(mmHg)           
Temp           
PR(beats/min)           
RR(breaths/min)           
 
 
 
 
BLOOD SUGAR ELECTROLYTES 
FBS(70-110 mgs/dl) SODIUM(135-145 mmol/l) CALCIUM(0.8-2.0 mmol/l) 
PPS(80-140 mgs/dl) POTASSIUM(3.5-5.1mmol/l) BICARABONATES 
RBS(70-170 gm/dl) CHLORIDE(97-106 mmol/l) 
 
HAEMATOLOGY 
Sl.No. Parameters Patient value Normal value 
1.  Hb  F: 11-16 gms/dl 
M: 11.5-18 gms/dl 
2.  RBC’S COUNT  4.0-6.0 million/cu.mm 
3.  HCT  35-60% 
4.  MCV  80-100 cu.micron 
5.  MCH  27-31 pg 
6.  MCHC  33-37% 
7.  RDW  11.6-13.7 % 
8.  MPV  7.8-11 cu.micron 
9.  WBC’S COUNT  4500-10500 cells/cu.mm 
10.  ESR  M:< 10 
F:< 20 
11.  CLOTTING TIME   5-10 min 
12.  BLEEDING TIME  1-6 min 
13.  PROTHROMBIN TIME   
14.  PLT  1.5-4.5 lakhs/cu.mm 
15.  PLATELETCRIT  0.17-0.35 % 
16.  PDW  9-4 cu.micron 
DIFFERENTIAL LEUKOCYTE COUNT   
17.  POLYMORPHS  42-75 % 
18.  LYMPHOCYTES  21-51 % 
19.  EOSINOPHILS  1-6 % 
20.  MONOCYTES  1-4 % 
LIVER  FUNCTION TEST 
TOTAL BILIRUBIN (0.4-1 mg/dl): S.TOTALCHOLESTEROL(<240mgs/dl): 
 
SGOT(0-40Iu/l): 
DIRECT BILIRUBIN (0.1-0.4 mg/dl): S.TRIGLYCERIDE (70-170mgs/dl): SGPT(0-65 Iu/l): 
INDIRECT BILIRUBIN (0.2-0.8 mg/dl): S.HDL(40-60mgs/dl): GGTP(11-45Iu/l): 
TOTAL PROTEIN (6-8 gms/dl): S.LDL(0-140mgs/dl): ALKP(0-258Iu/l): 
ALBUMIN (3.5-5.5 gms/dl): S.VLDL(0-38mgs/dl): GLOBULIN (2-3.5 gms/dl): 
  
 
 
 
 
TREATMENT CHART 
RENAL FUNCTION TEST Patient value Normal range 
S.UREA           20-40 mgs/dl 
URIC ACID  2.3-6.1 mg/dl 
S.CREATININE  0.6-1.40 mgs/dl 
IMAGING STUDY REPORT  
URINE EXAMINATION 
COLOUR SUGAR RBC 
TRANSPARENCY ALBUMIN PUS CELLS 
REACTION OCCULT BLOOD EPI. CELLS 
SPECIFIC GRAVITY KETONE BODY CAST & CRYSTALS 
BILE SALTS & BILE PIGMENTS WBC BACTERIA 
OTHER INVESTIGATION: 
DIAGNOSIS 
SL.
NO 
DRUG NAME DOSE FREQ ROA DAYS OF DRUG ADMINISTRATION 
D1 D2 D3 D4 D5 D6 D7 
1            
2            
 DRUG INTERACTION/ADVERSE DRUG REACTIONS 
 
DRUGS EFFECTS INFERENCE 
   
 
DISCHARGE MEDICATION 
 
                     DRUGS DOSE        FREQ DURATION OF THERAPHY 
     T.Name     G.Name    
1     
2     
3     
4     
5     
7     
8     
9     
10          
3            
4            
5  
 
          
6  
 
          
7  
 
          
8  
 
          
9  
 
          
10  
 
          
  



